Cipla InvaGen Signs Biosimilar Deal with Qilu for US Market

With pembrolizumab patent exclusivity narrowing and FDA's biosimilar approval pathway under 351(k) of the PHS Act drawing a growing field of applicants, Cipla's InvaGen unit has moved to secure commercial positioning in the US market through a partnership with China-based Qilu Pharmaceutical for a Keytruda biosimilar.

The agreement assigns InvaGen responsibility for US commercialization while Qilu contributes the biologics development and manufacturing infrastructure. For plant heads and supply-chain leads, the arrangement reflects a familiar split-capability model: a regulatory-experienced US commercial entity pairing with an established biologics manufacturer to compress the timeline from BLA submission to shelf placement. The structure places GMP compliance obligations squarely on Qilu's manufacturing sites, which will face FDA pre-approval inspection requirements before any US launch can proceed.

For QA directors tracking the pembrolizumab biosimilar landscape, the InvaGen-Qilu filing will enter a queue that already includes multiple 351(k) biosimilar applications referencing Merck's Keytruda. Demonstrating analytical and clinical similarity to a high-complexity PD-1 inhibitor requires robust comparability data packages; the regulatory affairs read here centers on how Qilu's characterization data withstands FDA's evidentiary standard for immunogenicity and pharmacokinetic equivalence.

Cipla has framed the deal as a portfolio-strengthening move in oncology biologics, consistent with InvaGen's existing US generics and specialty infrastructure. The commercial rationale is straightforward: pembrolizumab generated approximately $25 billion in global sales for Merck in 2024, making it among the highest-value biosimilar opportunities in the current patent cliff cycle. Regulatory affairs leads should note that US market entry timing will depend on both litigation outcomes under the Biologics Price Competition and Innovation Act patent dance provisions and the pace of FDA review.

The pre-approval inspection outcome for Qilu's manufacturing facility will serve as the first measurable checkpoint determining whether this partnership reaches US patients on the anticipated timeline.

Source: Media4Growth via Indian Pharma Post, 3 September 2026.